Deviating HER2 test results in gastric cancer: analysis from the prospective multicenter VARIANZ study

PURPOSE: The prospective multicenter VARIANZ study aimed to identify resistance biomarkers for HER2-targeted treatment in advanced gastric and esophago-gastric junction cancer (GC, EGJC). HER2 test deviations were found in 90 (22.3%) of 404 cases (central versus local testing) and were associated wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kolbe, Katharina, Haffner, Ivonne, Schierle, Katrin, Maier, Dieter, Geier, Birgitta, Luber, Birgit, Bläker, Hendrik, Wittekind, Christian, Lordick, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984518/
https://www.ncbi.nlm.nih.gov/pubmed/36030286
http://dx.doi.org/10.1007/s00432-022-04208-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984518/
https://www.ncbi.nlm.nih.gov/pubmed/36030286
http://dx.doi.org/10.1007/s00432-022-04208-6

Ejemplares similares